ES2150808T3 - Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico. - Google Patents

Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.

Info

Publication number
ES2150808T3
ES2150808T3 ES98114373T ES98114373T ES2150808T3 ES 2150808 T3 ES2150808 T3 ES 2150808T3 ES 98114373 T ES98114373 T ES 98114373T ES 98114373 T ES98114373 T ES 98114373T ES 2150808 T3 ES2150808 T3 ES 2150808T3
Authority
ES
Spain
Prior art keywords
anilida
carboxilico
trifluorometil
methylisoxazole
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98114373T
Other languages
English (en)
Inventor
Holger Dr Faasch
Udo Dr Hedtmann
Uwe Dr Westenfelder
Erich Dr Paulus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19734438A external-priority patent/DE19734438A1/de
Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Application granted granted Critical
Publication of ES2150808T3 publication Critical patent/ES2150808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION TRATA DE LA MODIFICACION CRISTALINA 2 DEL COMPUESTO DE FORMULA LA I, DEL PROCEDIMIENTO PARA LA OBTENCION DE LAS MODIFICACIONES CRISTALINAS 1 Y 2 Y DE SU UTILIZACION.
ES98114373T 1997-08-08 1998-07-31 Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico. Expired - Lifetime ES2150808T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19734438A DE19734438A1 (de) 1997-08-08 1997-08-08 Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de) 1997-12-17 1997-12-17 Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number Publication Date
ES2150808T3 true ES2150808T3 (es) 2000-12-01

Family

ID=26038983

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98114373T Expired - Lifetime ES2150808T3 (es) 1997-08-08 1998-07-31 Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
ES99117098T Expired - Lifetime ES2166205T3 (es) 1997-08-08 1998-07-31 Forma cristalina de amida del acido n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxilico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES99117098T Expired - Lifetime ES2166205T3 (es) 1997-08-08 1998-07-31 Forma cristalina de amida del acido n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxilico.

Country Status (28)

Country Link
US (5) US6060494A (es)
EP (2) EP0903345B1 (es)
JP (2) JPH11124372A (es)
KR (2) KR100544041B1 (es)
CN (2) CN1181064C (es)
AR (1) AR015418A1 (es)
AT (2) ATE207065T1 (es)
AU (1) AU752764B2 (es)
BR (1) BR9806568A (es)
CA (1) CA2245267C (es)
CZ (3) CZ292943B6 (es)
DE (2) DE59801792D1 (es)
DK (2) DK0987256T3 (es)
ES (2) ES2150808T3 (es)
GR (1) GR3034814T3 (es)
HK (2) HK1017681A1 (es)
HU (2) HU225870B1 (es)
ID (1) ID20667A (es)
IL (1) IL125671A (es)
NO (1) NO310871B1 (es)
NZ (1) NZ331270A (es)
PL (1) PL192126B1 (es)
PT (2) PT987256E (es)
RU (1) RU2224753C2 (es)
SK (2) SK282641B6 (es)
TR (2) TR200600582A1 (es)
TW (1) TW593288B (es)
UA (1) UA54411C2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
DE19908527C2 (de) 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CA2397601A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries, Ltd. Novel processes for making- and a new crystalline form of- leflunomide
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20050158371A1 (en) * 2002-02-12 2005-07-21 Sumitomo Pharmaceuticals Co., Ltd. Novel external agent
JPWO2003068239A1 (ja) * 2002-02-12 2005-06-02 住友製薬株式会社 新規外用剤
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
PL1507531T3 (pl) * 2003-03-12 2007-06-29 Teva Pharma Trwałe kompozycje farmaceutyczne desloratadyny
JP4223428B2 (ja) * 2004-03-31 2009-02-12 富士通メディアデバイス株式会社 フィルタおよびその製造方法
WO2007067710A1 (en) * 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) * 2006-09-15 2010-09-08 欣凯医药化工中间体（上海）有限公司 N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
UA103189C2 (ru) * 2008-03-10 2013-09-25 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма бензимидазольного соединения
NZ617025A (en) 2009-09-18 2014-03-28 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) * 2014-06-03 2016-02-17 江苏九九久科技股份有限公司 一种结晶方法
US9895370B2 (en) * 2015-11-19 2018-02-20 Pharmedix.Co., Ltd Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) * 2018-09-03 2019-01-11 深圳市新阳唯康科技有限公司 一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) * 2021-02-04 2022-11-08 美罗药业股份有限公司 一种来氟米特晶型i的制备方法
CN114716388B (zh) * 2021-11-04 2024-02-13 江苏冠军科技集团股份有限公司 一种磺胺-银化合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE2524959C2 (de) * 1975-06-05 1983-02-10 Hoechst Ag, 6000 Frankfurt 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
ES448386A1 (es) * 1975-06-05 1978-04-16 Hoechst Ag Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico.
DE2525959A1 (de) * 1975-06-11 1977-02-10 Focke Pfuhl Verpack Automat Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) * 1988-01-26 1990-06-19 Bristol-Myers Company Antiarthritic isoxazole-4-carboxamides
US5583150A (en) * 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
BR9008022A (pt) * 1990-05-18 1993-04-06 Hoechst Ag Amida de acido isoxazol-4-carboxilico e amidas de acido hidroxialquilideno-cianoacetico,medicamentos contendo estes compostos e sua aplicacao
DE4127737A1 (de) * 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) * 1992-04-30 1992-06-17 Roussel Lab Ltd Chemical compounds
ES2125356T3 (es) * 1993-01-08 1999-03-01 Hoechst Ag Empleo de leflunomida para la inhibicion de interleuquina 8.
ATE174218T1 (de) * 1993-01-08 1998-12-15 Hoechst Ag Verwendung von leflunomid zur hemmung von interleukin 1 beta
EP0607776B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
TW314467B (es) * 1993-03-31 1997-09-01 Hoechst Ag
GB9320299D0 (en) * 1993-10-01 1993-11-17 Roussel Lab Ltd Isoxazole derivatives
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
ATE194912T1 (de) * 1994-10-17 2000-08-15 Aventis Pharma Ltd Mittel zur vorsorge und heilung von typ i allergischen krankheiten
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) * 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) * 1997-06-16 1999-04-30 Lin-Hua Zhang Crystalline roxifiban
EP0903345B1 (de) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Kristallform von 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid
US6096770A (en) * 1998-08-03 2000-08-01 American Home Products Corporation Anthranilic acid analogs
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CA2397601A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries, Ltd. Novel processes for making- and a new crystalline form of- leflunomide
US6723855B2 (en) * 2000-02-15 2004-04-20 Teva Pharmaceutical Industries Ltd. Method for synthesizing leflunomide
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis

Also Published As

Publication number Publication date
CN1089759C (zh) 2002-08-28
HU225870B1 (en) 2007-11-28
HUP9801844A2 (hu) 2000-02-28
CN1208034A (zh) 1999-02-17
CZ246898A3 (cs) 1999-02-17
HK1049481B (zh) 2005-07-08
EP0987256A1 (de) 2000-03-22
DE59800287D1 (de) 2000-11-09
NO983632L (no) 1999-02-09
HU9801844D0 (en) 1998-10-28
TW593288B (en) 2004-06-21
KR20050077498A (ko) 2005-08-02
DK0903345T3 (da) 2000-10-23
EP0903345A1 (de) 1999-03-24
NO983632D0 (no) 1998-08-07
CN1373126A (zh) 2002-10-09
EP0903345B1 (de) 2000-10-04
UA54411C2 (uk) 2003-03-17
US20030027851A1 (en) 2003-02-06
GR3034814T3 (en) 2001-02-28
US6060494A (en) 2000-05-09
CA2245267A1 (en) 1999-02-08
PT987256E (pt) 2002-03-28
KR19990023433A (ko) 1999-03-25
HUP9801844A3 (en) 2000-04-28
NO310871B1 (no) 2001-09-10
ES2166205T3 (es) 2002-04-01
TR199801513A2 (xx) 1999-02-22
BR9806568A (pt) 2000-05-16
AU752764B2 (en) 2002-09-26
JPH11124372A (ja) 1999-05-11
JP2009280604A (ja) 2009-12-03
RU2224753C2 (ru) 2004-02-27
TR200600582A1 (tr) 2006-08-21
PT903345E (pt) 2001-01-31
HU0700190D0 (en) 2007-05-02
CZ292943B6 (cs) 2004-01-14
ID20667A (id) 1999-02-11
CZ301514B6 (cs) 2010-03-31
US6221891B1 (en) 2001-04-24
PL327901A1 (en) 1999-02-15
SK285216B6 (sk) 2006-09-07
EP0987256B1 (de) 2001-10-17
HK1017681A1 (en) 1999-11-26
TR199801513A3 (tr) 1999-02-22
IL125671A (en) 2002-11-10
KR100544041B1 (ko) 2006-09-18
DK0987256T3 (da) 2002-02-11
PL192126B1 (pl) 2006-09-29
ATE207065T1 (de) 2001-11-15
HK1049481A1 (en) 2003-05-16
US20030166945A1 (en) 2003-09-04
DE59801792D1 (de) 2001-11-22
CN1181064C (zh) 2004-12-22
CZ301426B6 (cs) 2010-02-24
CA2245267C (en) 2008-12-23
KR100588254B1 (ko) 2006-06-12
AR015418A1 (es) 2001-05-02
US20040204465A1 (en) 2004-10-14
HU229232B1 (en) 2013-09-30
AU7887098A (en) 1999-02-18
IL125671A0 (en) 1999-04-11
SK282641B6 (sk) 2002-10-08
NZ331270A (en) 2000-04-28
US6552202B2 (en) 2003-04-22
SK105898A3 (en) 1999-02-11
ATE196764T1 (de) 2000-10-15
US6995272B2 (en) 2006-02-07
US6900334B2 (en) 2005-05-31

Similar Documents

Publication Publication Date Title
ES2150808T3 (es) Forma cristalina de (4-trifluorometil)-anilida de acido 5-metilisoxazol-4-carboxilico.
HN1997000110A (es) Derivados del acido arilsulfoonilamino hidroxamico
ES2070660B1 (es) Un procedimiento para la preparacion de 2,5-damino-3-hidroxihexanos sustituidos, utiles como inhibidores de proteasas retrovirales.
DE69937077D1 (de) Zwischenprodukte für die Herstellung von Imidazo-Pyridin-Derivate
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
HN1999000131A (es) Derivados del acido hidroxi pipecolato hidroxamico.
NO20012995L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
ECSP034917A (es) Nuevos derivados de acido sulfonico
IT1298535B1 (it) Procedimento per la produzione di gamma-butirrolattone
PA8467301A1 (es) Nuevos derivados del acido dihidroxihexanoico
SE9801494D0 (sv) Novel use
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
IT1298096B1 (it) Procedimento per la produzione di gamma-butirrolattone
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
ECSP003590A (es) Compuestos calcioliticos
MX26167A (es) Derivados de acido piridil-benzoico para el tratamiento de enfermedades relacionadas con lecotrino.
BR0013751A (pt) Processo para produção de derivados de ácido naftiridina-3-carboxìlico
BR0212153A (pt) Compostos e respectivos processos de preparação e de isolamento de dicloreto de 2-difluormetilornitina
ES2168355T3 (es) Derivados de bisulfuro de indano-2-mercaptoacetilamida utiles como inhibidores de la encefalinasa.
IT1303759B1 (it) Procedimento migliorato per la preparazione di acido 7-azaindolil-3-carbossilico.
ES2146772T3 (es) Derivados de imidoacidos y su empleo como pesticidas.
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 903345

Country of ref document: ES